We are in strong support of HAB’s proposal included in the Federal Register on November 10, 2025, to update the funding formulas used by the Ryan White HIV/AIDS Program (RWHAP) for allocating Part A and Part B funding. This welcome change is long overdue and will increase equity in the distribution of funding and better match the level of funding with the number of RWHAP clients residing in a jurisdiction.
We joined with the Arthritis Foundation on a letter signed by 20 patient groups to HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Oz regarding TrumpRx, thanking them for their efforts for lowering Rx costs, but highlighting the need to ensure that patients are aware that their costs do not count towards their insurance requirements and cost-sharing.
The HIV+Hepatitis Policy Institute strongly urges the Advisory Committee on Immunization Practices (ACIP) to maintain the recommendation of a universal hepatitis B birth dose in the United States. Maintaining this requirement will not only help prevent people from becoming ill but result in ending hepatitis B in our country, which is still a highly infectious disease.
In July, we wrote to you to urge you you to cover all PrEP medications and services without cost-sharing, and not to employ prior authorization for the purpose of steering employees to one PrEP drug or another, as is required of all non-grandfathered commercial insurance plans in the United States. On August 23, 2025, you replied, assuring us that the enrollee notice we had brought to your attention had been “sent inadvertently,” and that Delta would “cover all three formulations of PrEP without cost-sharing subject to the terms and conditions of the plans.” Unfortunately, we now have learned that Delta Air Lines intends to impose prior authorization requirements to steer employees and their family members who use PrEP to the generic formulation of PrEP effective October 1, 2025.
We, the undersigned 64 organizations, on behalf of people and communities affected by HIV, their care providers, public health practitioners, and community-based organizations, write in response to statements made by CVS Health to the media that it does not intend to cover Yeztugo (lenacapavir), a twice-yearly long-acting injectable drug recently approved by the FDA as pre-exposure prophylaxis (PrEP) for the prevention of HIV.[1] We urge you to reconsider this decision and cover Yeztugo without delay.